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Introduction
Irritable bowel syndrome (IBS) is a chronic, 
cyclic, and relapsing functional bowel disorder 
characterized by abdominal pain associated with 
changes in bowel habit or abdominal distention. 
It affects up to 11.5% of the general population in 
Europe and developing countries [Hungin et al. 
2003]. In addition to the impact on patient’s 
health, IBS is also associated with impaired qual-
ity of life, diminished work productivity and 
increased health and economic costs [Agarwal 
and Spiegel, 2011]. Although there is consensus 
on the application of clinical Rome Criteria to 
diagnose IBS and its subtypes [Longstreth et al. 
2006], up to 50% of patients still remain undiag-
nosed [Hungin et al. 2003]. In addition, there is a 
lack of consensus on IBS treatment in terms of 
optimal pharmacological treatment, most useful 
drugs, specific indications for spasmolytic agents, 
timing of clinical response and duration of 
treatment.
Otilonium Bromide (OB) is a musculotropic spas-
molytic agent belonging to the family of quater-
nary ammonium derivatives and successfully used 
in the treatment of patients affected by IBS due to 
its specific pharmacokinetic and pharmacody-
namic properties. The positive polarity of the head 
of the OB molecule determines the main pharma-
cokinetic property of this drug: a minimal systemic 
absorption and the consequently high safety pro-
file. Studies on animal models revealed a specific 
OB accumulation in colonic circular muscle at 
therapeutic µm concentrations, while its plasma 
levels were 1000 times lower, together with a poor 
penetration of the drug in the central nervous 
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Background: Otilonium bromide (OB) is a spasmolytic agent acting as an L-type calcium 
channel antagonist in intestinal and colonic smooth muscle cells (SMCs). We analyzed 
three independent clinical trials with homogeneous design on patients with irritable bowel 
syndrome (IBS). After 2 weeks receiving placebo, patients were randomized to receive OB (3 × 
40 mg daily) or placebo for 15 weeks. We aimed to perform a pooled analysis of the data from 
these homogeneous clinical trials to evaluate the efficacy of OB treatment on symptoms and 
global response of patients.
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(c) severity of bloating; (d) rate of responders as evaluated by physicians (55% at week 10 and 
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system [Evangelista et al. 2000]. Consistently, after 
oral administration to healthy volunteers, the OB 
plasmatic concentration was very low, <1% of the 
drug was eliminated by urine, and 97% was elimi-
nated by feces [Evangelista, 2004].
Recent clinical studies showed comparable safety 
and tolerability for OB and placebo [Clave et al. 
2011]. OB was shown to inhibit the main patterns 
of human sigmoid motility in vitro, including: the 
tone of smooth muscle cells (SMCs); the rhyth-
mic phasic contractions induced by the interstitial 
cells of Cajal; and the strong contractions induced 
by stimulation of enteric motor neurons mainly 
by blocking the calcium influx through L-type 
calcium channels on SMCs [Gallego et al. 2010]. 
Recent in vitro studies using cultured human 
colonic SMCs to further assess the musculotropic 
spasmolytic properties of OB confirmed that this 
drug causes smooth muscle relaxation through 
the inhibition of voltage-gated calcium channels 
(L-type > T-type) and the inhibition of mus-
carinic and tachykinergic effects [Martinez-
Cutillas et  al. 2013]. All the above described 
pharmacodynamic properties mediate the muscu-
lotropic spasmolytic effects of OB. In addition, its 
interaction with the NK1/NK2 tachykinergic 
receptors in sensory afferent nerves may also 
improve the visceral hypersensitivity that affects 
patients with IBS [Rychter et al. 2014].
We included in the present analysis three rand-
omized, double-blind, placebo-controlled studies 
with a homogeneous treatment schedule of 3 ×  
40 mg OB daily for 15 weeks to measure the clini-
cal efficacy of OB in patients with IBS. The first 
study was conducted in 23 Italian centers, and 
enrolled 325 patients with IBS [Battaglia et  al. 
1998]; the second study was conducted in 34 cent-
ers in eight European countries and enrolled 355 
patients with IBS [Clave et  al. 2011]; the third 
study was conducted in Greece and enrolled 203 
patients with IBS [Menarini IFR, 2012]. In all 
these studies, OB improved the main symptoms of 
patients with IBS, mostly related to abdominal 
pain. Drawbacks included the difficult translation 
of results to clinical practice for both patients and 
physicians due to the long-term primary endpoints 
(15 weeks), the need to define a global treatment 
response on the basis of improvements in the most 
frequent symptoms reported by patients and a strict 
intention-to-treat (ITT) analysis, and the relevant 
placebo effect [Ford et al. 2008; Clave et al. 2011; 
Desborough and Ford, 2011; Hungin, 2011].
In the current analysis, we collected the individ-
ual data from the three homogeneous rand-
omized controlled trials (RCTs) described above 
[Battaglia et al. 1998; Clave et al. 2011; Menarini 
IFR, 2012] and performed a pooled analysis, with 
the aim of evaluating the efficacy of OB treatment 
on the main IBS symptoms (including intensity 
and frequency of abdominal pain, severity of 
bloating, stool frequency and consistency), and 
the global treatment response assessed by patients 
and by their physicians. The results of the pooled 
analysis support the significant therapeutic effect 
of OB versus placebo, thus providing additional 




A total of 889 patients with IBS were enrolled in 
three independent RCTs [Battaglia et  al. 1998; 
Clave et al. 2011; Menarini IFR, 2012]. In more 
detail, the study by Battaglia and colleagues evalu-
ated the efficacy of OB by comparing 158 patients 
treated with the study drug versus 158 patients 
receiving a placebo (study code in the pooled anal-
ysis: Battaglia) [Battaglia et al. 1998]. The primary 
objective of the OBIS study was to confirm the 
efficacy of OB for symptom control in patients 
with IBS in a superiority trial versus placebo by 
comparing 169 patients receiving the study drug 
versus 170 patients receiving a placebo (study code 
in the pooled analysis: OBIS) [Clave et al. 2011]. 
The third study was conducted in Greece and 
evaluated the efficacy of OB by comparing 88 
patients with IBS treated with the study drug ver-
sus 96 patients receiving a placebo (study code in 
the pooled analysis: Greek) [Menarini IFR, 2012]. 
The inclusion/exclusion criteria and the design 
(RCT, OB versus placebo) of the three studies 
were homogeneous and included: (a) age > 18 
years; (b) exclusion of major organic disease in 
patients with age >50 years; (c) a positive diagno-
sis of IBS established using similar clinical criteria 
(Rome I in the Battaglia and the Greek studies 
and Rome II in the OBIS study) [Thompson 
et al. 1999]; (d) after a run-in period of 2 weeks of 
single blind placebo treatment, mild-to-severe 
symptomatic IBS patients were randomized to 
receive treatment in a double-blinded manner: 
OB, 3 tablets (3 × 40 mg) daily before meals 
(120 mg OB/day) or matching placebo, 3 tablets 
daily before meals as well, for 15 weeks. Patient 
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symptoms were monitored by means of diaries. 
Follow-up visits were scheduled after 5, 10 and 15 
weeks of treatment.
Efficacy variables
The following efficacy parameters included in this 
analysis were considered as primary efficacy vari-
ables in the three selected studies [Battaglia et al. 
1998; Clave et  al. 2011; Menarini IFR, 2012]: 
(1) intensity of abdominal pain as reported by 
patients through a score; (2) intensity of abdomi-
nal pain evaluated by visual analogue scale (VAS) 
as reported by patients; (3) number of episodes of 
abdominal pain as reported by patients; (4) inten-
sity and frequency of abdominal pain by type of 
IBS; (5) responder patients by global evaluation of 
pain as composite parameter of intensity and fre-
quency scores; (6) stool frequency and consist-
ency; (7) severity of bloating; and (8) responder 
patients as evaluated by the physician.
Intensity of abdominal pain was assessed by 
adapting the 4-level rating scale, where 0 = 
absent, 1 = mild/moderate, 2 = severe, and 3 = 
extremely severe, to the three RCTs selected for 
this analysis.
Weekly frequency of episodes of abdominal pain 
was assessed by adapting the 4-level rating scale 
where score 0 = none, 1 = 1–3 episodes, 2 = 4–7 
episodes and 3 = 8 or more episodes during the 
week to the three RCTs selected for this analysis.
As a global measure of treatment response, a 
composite pain score (global evaluation of pain 
as composite parameter of intensity of pain and 
episodes of pain as reported by patients) was 
calculated for this study as: abdominal pain score 
× score for episodes of pain.
Severity of bloating was scored using a scale 
where 0 = absent; 1 = mild-to-moderate; 2 = 
severe; and 3 = extremely severe.
Intensity, frequency and global evaluation of 
abdominal pain and severity of bloating were 
recorded in a diary for 2 weeks before randomiza-
tion. The worst score recorded during the 2 weeks 
was used as the baseline score for further analysis. 
During the follow up, the scores were recorded in 
the diary every week. The score recorded in the 
last week before the follow-up visit was used for 
the analysis.
Follow-up data were analyzed in an ITT analysis. 
Responders with regards to intensity, frequency, 
global evaluation of pain as a composite index of 
intensity and frequency, or severity of distention, 
were defined as patients having a reduction of 
score ⩾1 after 5, 10, and 15 weeks of treatment. 
The intensity of abdominal pain was also reported 
by patients using a VAS at baseline and at the end 
of treatment.
The stool frequency was measured by the number 
of days without stools and the average number of 
stools in the remaining days of the week reported 
by patients. The latter was evaluated by a four-
level scale where: 0 = 1 per day; 1 = 2 per day; 2 
= 3 or 4 per day; and 3 = 5 or more per day. 
Results on stool consistency reported by patients 
were transformed into a dichotomous variable, 
where: 0 = normal consistency and 1 = abnormal 
consistency (either loose or hard).
Responders were also examined according to the 
global efficacy assessment evaluated by the physi-
cian using a 4-point score at each visit after rand-
omization: 0 = no efficacy; 1 = moderate efficacy; 
2 = good efficacy; and 3 = excellent efficacy. 
Responders were defined as patients showing 
good or excellent improvement in the global eval-
uation by the physician.
The efficacy analysis was based on an ITT popu-
lation analysis. The full analysis set (FAS, ITT 
population) included all randomized patients 
who had taken at least one dose of the study drug 
and had undergone at least one efficacy assess-
ment for the primary efficacy endpoint (evalua-
tion of the diaries) after baseline.
Methods for the pooled analysis
All the efficacy data derived from the three stud-
ies were reported individually per study and as 
weighted averages taking into account the num-
ber of patients enrolled in each study. First, an 
analysis of variance (ANOVA) was used for the 
direct comparison between treatment groups, 
and then a general linear model (GLM) was used 
for the comparisons in which an impact of covari-
ates was expected. Data were statistically ana-
lyzed using the analysis of covariance, including 
baseline intensity, sex, age, body mass index 
(BMI) as covariates and treatment as factor. The 
GLM was used to compare the efficacy parame-
ters between the treatment groups considering 
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the model baseline values of each parameter, age, 
sex and BMI as covariates. The GLM procedure 
provides regression analysis and ANOVA for one 
dependent variable (efficacy parameter) by more 
factors (treatment group and sex) and covariates 
(baseline values, age and BMI).
The same method used for the analysis of the 
end-of-treatment data (week 15) was applied to 
the data obtained at the intermediate visits (weeks 
5 and 10).
Severity of pain assessed by VAS was analyzed 
using ANOVA performed on changes from base-
line to the end of treatment.
Frequency tables were completed at each relevant 
time point for the rate of responders. Treatment 
responders were analyzed using a binary logistic 
regression model including factors for treatment. 
For an exploratory subgroup analysis, the follow-
ing three subgroups were defined according to 
the IBS type: predominant diarrhea (IBS-D), 
predominant constipation (IBS-C), mixed type 
(IBS-M) [Thompson et al. 1999; Longstreth et al. 
2006]. The same descriptive statistics on change 
from baseline in the frequency of abdominal pain 
for the whole population were provided in the 
FAS, stratifying by subgroup category.
Results were also represented through forest 
plots, designed to illustrate the relative strength of 
treatment effects in multiple quantitative studies 
addressing the same question. The vertical line in 
a forest plot corresponds to lack of effect. If the 
confidence intervals (CIs) for individual studies 
do not overlap with this line, it demonstrates that, 
at the given level of confidence (95%), their effect 
sizes differ from no effect. The same applies for 
the pooled measure of effect (pooled dataset): if 
the CI for the pooled dataset does not overlap 
with the vertical line corresponding to lack of 
effect, the overall result of pooled analysis differs 
from no effect at the 95% level of confidence. 
The analysis was performed in SAS (version 9.02, 
SAS Institute Inc, Raleigh, NC, USA).
Results
Demographic data of patients included in the 
pooled analysis
The patient population recruited in the three 
RCTs selected for the pooled analysis of the data 
consisted of 883 patients of both sexes, with a 
prevalence of women (69.8%), and a median age 
of 46.2 years, as summarized in Table 1. No sig-
nificant differences were observed between the 
two treatment groups with respect to demo-
graphic data in the three studies. Table 1 also 
includes the baseline clinical features of enrolled 
patients suffering mild-to-severe IBS, with >3 
episodes of abdominal pain per week, with mod-
erate-to-severe pain intensity, moderate-to-severe 
bloating, and abnormal stool consistency. IBS 
subtypes could only be derived from studies by 
Battaglia and OBIS, and included 25.2% patients 
with IBS-D, 31% with IBS-C and 43.8% with 
IBS-M. No differences in baseline clinical fea-
tures were observed between OB and placebo 
groups (Table 1). Mean treatment compliance 
was high and comparable in both treatment 
groups at all visits, ranging from 95% to 97%, 
and the dropout rates were 16.1% in both the 
treatment groups.
OB effect on intensity of abdominal pain
A significant placebo effect was observed from 
week 5 (p < 0.001), as abdominal pain score 
decreased significantly both in the OB group and 
the placebo group at the end of the treatment 
(Figure 1). However, the comparison between 
treatment groups of the abdominal pain score 
reduction from baseline showed a greater effect in 
the OB group in comparison with placebo at all 
visits with significant differences at week 10 and 
week 15 for this primary endpoint (Figure 1). 
The GLM model, providing regression analysis 
and ANOVA for abdominal pain score reduction 
by more factors (treatment group and sex) and 
covariates (baseline value of abdominal pain 
score, age and BMI), also revealed a significant 
therapeutic effect of OB versus placebo at week 10 
(p = 0.009) and 15 (p = 0.006) (Figure 1). The 
proportion (%) of OB/placebo responders with 
regards to intensity of pain was 42.5/36.2 at week 
5; 52.7/44.5 at week 10 and 67.1/50.0 at week 15. 
Figure 2a depicts the forest plot of responders 
according to the intensity of pain evaluated by the 
patients, showing a strong therapeutic effect of 
OB versus placebo after 10 and 15 weeks of treat-
ment. In addition, the analysis of VAS on abdom-
inal pain at the end of treatment showed significant 
improvement of VAS scores for OB, as well as for 
placebo treatment, 2.03 ± 1.74 for OB and 2.44 
± 2.23 for placebo (p = 0.009). Regarding IBS 
subtype analysis, we observed a tendency towards 
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a greater reduction of abdominal pain intensity 
with OB in comparison with placebo in all groups 
at all visits, reaching a significance at week 15 if 
all groups were pooled together (p = 0.020). The 
reduction of pain intensity by OB was statistically 
significant also in the group of patients with pre-
dominant IBS-M (week 15, p = 0.015).
OB effect on the frequency of abdominal pain as 
reported by patients
A significant placebo effect was observed from 
week 5 (p < 0.001) and at the end of the treat-
ment in the scores of weekly number of episodes 
of abdominal pain. They decreased significantly 
both in the OB group and in the placebo group 
(Figure 3). However, the comparison between 
groups showed a favorable trend in the OB group 
in comparison with placebo, with significant dif-
ferences at week 10 and week 15 by ANOVA and 
at week 15 by GLM (p = 0.002) (Figure 3). The 
proportion (%) of OB/placebo responders with 
regards to the reduction of number of episodes of 
abdominal pain was 54.5/47.4 at week 5; 
67.4/58.6 at week 10 and 73.0/60.6 at week 15. 
Figure 2b depicts the forest plot of frequency of 
abdominal pain evaluated by the patient, showing 
a strong therapeutic effect of OB versus placebo 
after 10 and 15 weeks of treatment. The compari-
son for IBS subtypes found significant differences 
(OB versus placebo) in the group of patients with 
predominant IBS-C (week 10, p = 0.031 and 
Table 1. Demographic and baseline features of the patients included in the pooled analysis (Safety 
population).
Parameter OB (n = 442) Placebo
(n = 441)
p-value
Age (mean ± SD) 46.9 ± 14.8 46.3 ± 15.6 0.575
Sex [n (%)]  
 Females 310 (70.3) 304 (69.2) 0.735
 Males 131 (29.7) 135 (30.8)  
BMI (mean ± SD) 24.4 ± 4.1 24.1 ± 4.1 0.690
Smoker status [n (%)]  
 No + ex 338 (76.5) 334 (75.7) 0.798
 Smoker 104 (23.5) 107 (24.3)  
Alcohol [n (%)]  
 No 343 (78.0) 328 (74.5) 0.235
 Average 97 (22.0) 112 (25.5)  
 Number of subjects in the ITT population (% of 
safety population)
415 (93.9) 424 (96.1)  
 Dropout rates 71 (16.1) 71 (16.1) ns
Baseline features  
 Intensity of abdominal pain (score, mean ± SD) 1.36 ± 0.58 1.37 ± 0.62 0.844
 Intensity of abdominal pain (VAS, mean ± SD) 5.00 ± 2.14 4.92 ± 2.06 0.593
 Frequency of abdominal pain (mean ± SD) 1.81 ± 0.69 1.72 ± 0.72 0.066
 Global pain index (mean ± SD) 2.71 ± 1.82 2.49 ± 1.68 0.087
IBS subtype (%)  
 IBS-D 25.7 24.7  
 IBS-C 28.1 33.8 ns
 IBS-M 46.2 41.5  
 Stool frequency (mean ± SD) 0.63 ± 0.54 0.60 ± 0.54 0.472
 Normal stool consistency (%) 26.1 30 0.25
 Severity of bloating (mean ± SD) 1.37 ± 0.73 1.31 ± 0.705 0.284
BMI, body mass index; IBS, irritable bowel syndrome; IBS-C, IBS with predominant constipation; IBS-D, IBS with 
predominant diarrhea; IBS-M, mixed type IBS; ITT, intention-to-treat; ns, not significant; OB, otilonium bromide; SD, 
standard deviation; VAS, visual analogue scale.
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week 15, p = 0.032), IBS-M (week 15, p < 0.001) 
and in all groups combined (week 5, p = 0.044, 
week 10, p = 0.011 and week 15, p < 0.001).
OB effect on global evaluation of pain index and 
treatment response by patients
A significant placebo effect was observed at week 5 
(p < 0.001) and at the end of treatment for the 
global evaluation of pain index considering intensity 
and frequency of abdominal pain which decreased 
significantly both in the OB and in the placebo group 
(Figure 4). However, the comparison between treat-
ment groups of this global index of response showed 
a greater reduction in the OB group versus the pla-
cebo group, with significant differences at week 
10 and week 15 (by ANOVA), and at week 15 
(p = 0.003) following the regression analysis in the 
GLM (Figure 4). The proportion (%) of OB/pla-
cebo responders with regards to the global evalua-
tion of pain was 60.5/54.9 at week 5; 71.8/62.4 at 
week 10 and 77.2/65.8 at week 15. Figure 2c depicts 
the forest plot of weekly global evaluation of treat-
ment response evaluated by patients, also showing a 
strong therapeutic effect of OB versus placebo after 
10 and 15 weeks of treatment.
OB effect on stool frequency and consistency
Baseline data on stool frequency and consist-
ency are summarized in Table 1. During the 
Figure 1. Reduction (difference versus baseline) of 
abdominal pain intensity score (ITT pooled dataset). 
p = ANOVA p-value. *p < 0.05 in the GLM (both 
significant at week 10 and 15).
ANOVA, analysis of variance; GLM, general linear model; 
ITT, intention-to-treat; OB, otilonium bromide.
Figure 2. Forest plots including results from the pooled analysis on the primary efficacy variables from 
Battaglia and colleagues [Battaglia et al. 1998], OBIS [Clave et al. 2011], and Greek [Menarini IFR, 2012] 
studies. (a) Responder patients according to intensity of pain evaluated by the patient (ITT pooled dataset, 
week 15); (b) Responder patients according to number of episodes of abdominal pain evaluated by the patient 
(ITT pooled dataset, week 15); (c) Responder patients according to global evaluation of pain evaluated by the 
patient (ITT pooled dataset, week 15); (d) Responder patients according to severity of bloating score evaluated 
by the patient (ITT pooled dataset, week 15); (e) Responder patients according to global efficacy assessment 
evaluated by the physician.
ITT, intention-to-treat; OB, otilonium bromide.
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treatment, the stool frequency score decreased 
significantly both in the OB group and in the pla-
cebo group (Figure 5). The analysis included 
patients with all evaluations recorded at sched-
uled visits (baseline, week 5, week 10, and week 
15). The comparison between treatment groups 
showed a trend for a greater reduction of stool 
frequency in the OB group in comparison with 
placebo, but without significant differences at any 
time point (Figure 5). Final scores for stool 
frequency at week 15 were 0.35 ± 0.50 for 
patients treated with OB and 0.43 ± 0.64 for 
patients receiving the placebo (p = 0.76, ns). 
Regarding stool consistency, both groups of 
patients showed an improvement during the 
treatment period. However, OB administration 
increased the prevalence of patients with normal 
stools during treatment visits versus patients 
receiving the placebo, with significant differences 
at week 5, with 61.6% patients with normal stools 
in the OB group and 53.9% in the placebo group 
(p = 0.043). At the end of treatment, after 15 
weeks, 74.8% patients in the OB group and 
68.5% patients in the placebo group presented 
normal stool consistency (p = 0.084, ns).
OB effect on severity of bloating/distension
A relevant placebo effect was observed from week 
5 (p < 0.001) in reference to evaluation of bloat-
ing/distension. At the end of the treatment, the 
severity of bloating score decreased significantly 
both in the OB group and in the placebo group. 
However, the pooled analysis revealed a greater 
reduction of bloating in the OB group versus the 
placebo at all visits, with significant differences at 
week 10 and week 15 (Figure 6). The GLM 
model, providing a regression analysis for the 
severity of bloating score reduction by more fac-
tors and covariate, also revealed a significant ther-
apeutic effect of OB versus placebo at week 10 
(p = 0.016) and 15 (p = 0.037). The proportion 
(%) of OB/placebo responders with regards to the 
Figure 3. Reduction of the number of episodes of 
abdominal pain score (ITT pooled dataset). 
p = ANOVA p-value. *p < 0.05 in the GLM at week 15.
ANOVA, analysis of variance; GLM, general linear model; 
ITT, intention-to-treat; OB, otilonium bromide.
Figure 4. Reduction of the global evaluation of pain 
index (ITT pooled dataset).
p = ANOVA p-value. *p < 0.05 in the GLM at week 15.
ANOVA, analysis of variance; GLM, general linear model; 
ITT, intention-to-treat; OB, otilonium bromide.
Figure 5. Reduction of stool frequency (ITT pooled 
dataset). p = ANOVA p-value.
ANOVA, analysis of variance; ITT, intention-to-treat; OB, 
otilonium bromide.
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severity of bloating was 43.8/40.8 at week 5; 
57.7/49.1 at week 10 and 59.2/53.7 at week 15. 
Figure 2d depicts the forest plot of responders 
according to severity of bloating evaluated by 
patients, showing a significant effect of OB after 
15 weeks of treatment.
OB effect on responders evaluated by 
physicians
The proportion (%) of OB/placebo responders 
according to global evaluation of IBS symptoms 
assessed by physicians was 62.6/46.5 at week 5; 
74.6/59.7 at week 10 and 79.1/67.3 at week 15. 
The physicians considered the global efficacy as 
good or excellent for 38.5% (week 5), 55.0% 
(week 10) and 63.9% (week 15) of patients 
treated with OB. Figure 2e depicts the forest plot 
of responder patients according to the global eval-
uation of pain score, highlighting an overall rele-
vant and significant therapeutic effect of OB 
versus placebo.
Discussion
The pooled analysis we performed reveals that 
OB is more effective than placebo in the treat-
ment of the most relevant symptoms of IBS and 
in the global response to treatment assessed both 
by physicians and by patients. The second finding 
of the pooled analysis is related to the timing of 
the therapeutic benefit of OB compared with pla-
cebo: for most of the efficacy variables, the spe-
cific improvement that can be attributed to OB 
started after 10 weeks of treatment and was 
maximal and stable until the end of treatment 
(at week 15).
The results from this pooled analysis are sup-
ported by the strength of its design, with three 
independent but homogeneous studies, an ITT 
analysis, a rigorous assessment of the placebo 
effect, equal dropout rates, global efficacy out-
comes evaluated by patients and physicians, and 
the statistical approach, which included a binary 
logistic regression model and forest plots. The 
rationale for the specific inclusion of the Battaglia, 
the OBIS and the Greek studies in the pooled 
analysis is that they are RCTs with the same 
experimental design, including a total of 883 
patients, thus providing a large study population 
to evaluate the efficacy of OB treatment versus 
placebo on the main symptoms and global 
response of patients with IBS.
This analysis includes some unpublished data, 
originating from a RCT conducted in Greece and 
filed by a local pharmaceutical company that pro-
duced the drug. The results of the unpublished 
(Greek) study are similar to those obtained in the 
other studies (Battaglia and OBIS) included in 
this analysis (Figure 2a and 2b) and, in some 
cases, worse than those reported in the OBIS 
study in reference to the frequency of abdominal 
pain, the global composite score of pain, and the 
responder rates. Overall, our results show OB 
treatment is globally effective in a representative 
population of patients with mild-to-severe IBS of 
different subtypes, further supporting its intro-
duction to clinical practice.
OB has specific pharmacodynamic characteris-
tics, allowing it to counteract the increased pain 
sensitivity and the impaired small bowel and 
colon motility that characterize IBS [Drossman 
et al. 2002]. Visceral hypersensitivity is associated 
with the intensity of abdominal pain, while 
impaired colonic motility (hypercontractility, 
hyperreactivity and increased tone) is associated 
with frequency of pain episodes and with impaired 
bowel habits [Kanazawa et  al. 2008]. Patients 
with IBS are thought to present abdominal pain 
following stimulation of sensitive nerve endings 
located in the intestinal wall by strong tonic or 
phasic intestinal contractions in a context of low 
Figure 6. Reduction (difference versus baseline) of 
severity of bloating-meteorism score (ITT dataset). 
p = ANOVA p-value. *p < 0.05 in the GLM at week 10 
and 15.
ANOVA, analysis of variance; GLM, general linear model; 
ITT, intention-to-treat; OB, otilonium bromide.
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threshold of stimulation due to visceral hypersen-
sitivity [Clave, 2011]. The mechanisms of action 
of OB in colonic muscle cells, colonic motility 
patterns and primary afferent neurons have been 
recently revised [Rychter et  al. 2014]. Studies 
demonstrated a reduction in visceral sensitivity to 
rectal balloon distention in IBS patients following 
treatment with OB [Baldi et al. 1992; Czimmer 
et al. 2001]. The combined action of OB on nor-
malization of exaggerated motility patterns and 
inhibition of primary afferent nociceptors proba-
bly underlies the strong therapeutic effects of this 
drug on frequency and intensity of abdominal 
pain in IBS patients.
The first observation resulting from this pooled 
analysis is the relevant placebo effect observed in 
all efficacy variables, increasing from the begin-
ning of treatment with a proportion of placebo 
responders with regards to the global evaluation 
of pain index of 54.9–65.8% patients from week 5 
to week 15. This effect is well known in IBS stud-
ies. For example, it was measured previously in a 
meta-analysis of 45 placebo-controlled studies 
and found to be highly variable, ranging from 
16–71%, with an average of >40% [Patel et  al. 
2005]. Slightly higher rates of placebo response 
were also observed in the OBIS study [Clave et al. 
2011] and were attributed to the entry criteria of 
the study, which included patients with severe 
IBS symptoms and hence with a greater chance 
for spontaneous improvement, considering the 
cyclic nature of IBS.
The second relevant result from our pooled analy-
sis is the strong therapeutic effect of OB, greater 
than the placebo response in almost all the primary 
efficacy variables (intensity and frequency of pain, 
bloating and patient response outcomes, such as 
global evaluation of pain considering both inten-
sity and frequency of episodes and VAS, and global 
efficacy evaluated by physicians). A previous meta-
analysis by Poynard and colleagues, including four 
ancillary clinical studies with OB, also found a sig-
nificant effect of this drug on the proportion of 
patients showing an improved global assessment 
(odds ratio of 2.33; 95% CI: 1.60 ± 3.40), and an 
improvement in pain and distention at the end of 
treatment [Poynard et al. 2001]. A meta-analysis 
by Lesbros-Pantoflickova found that when exclud-
ing the low-quality trials, an improvement of 
global IBS symptoms with all antispasmodics was 
maintained only for OB, but on the basis of only 
two studies [Lesbros-Pantoflickova et  al. 2004]. 
Finally, a meta-analysis by Ford and colleagues, 
including the same four studies selected by 
Poynard and colleagues, also suggested a benefi-
cial effect for OB, as symptoms of IBS persisted 
in 51% patients treated with OB and in 71% 
patients treated with placebo [Ford et al. 2008]. 
However, these last authors underlined a signifi-
cant heterogeneity among designs and endpoint 
of studies, as the sample size in three studies 
was small, the duration of treatment varied, 
and the largest trial [Glende et al. 2002] showed 
only a modest benefit of OB in the rate of 
monthly responders, corresponding to 11–14% 
[Desborough and Ford, 2011]. The OBIS study 
included in this pooled analysis found an effect of 
OB in the reduction of episodes of abdominal 
pain, reduction of abdominal bloating, global effi-
cacy by patient assessment and protection from 
IBS symptom relapse significantly greater than 
placebo at the end of the 15-week treatment 
period (primary endpoint) [Clave et al. 2011]. In 
addition, safety and tolerability of OB was very 
high and similar to placebo, a result consistent 
with Poynard and colleagues’ meta-analysis 
[Poynard et al. 2001; Clave et al. 2011]. A study 
conducted on Asian patients confirmed the effec-
tiveness of OB in alleviating IBS symptoms 
[Chang et al. 2011]. A recent literature review of 
the efficacy and tolerability of OB in the long-term 
management of patients with IBS confirmed that 
this drug reduces abdominal pain and discomfort 
in patients with IBS, exhibiting greater efficacy 
and tolerability than placebo or other similar drugs 
[Triantafillidis and Malgarinos, 2014]. Finally, a 
very recent study aiming at evaluating the dose-
response relationship of 20 mg, 40 mg, 80 mg of 
OB or placebo administered three times daily for 
4 weeks on functional or clinical efficacy IBS vari-
ables demonstrated that 40 mg and 80 mg of OB 
can improve individual and global clinical symp-
toms of IBS compared with placebo over a 4-week 
period [Chmielewska-Wilkon et al. 2014]. Another 
recent literature review found OB was effective 
also in comparison with other drugs, such as 
pinaverium bromide and mebeverine, with a 
favorable tolerability profile [Forte et al. 2012].
Overall, all these studies clearly prove that OB is 
well tolerated and is able to improve the symp-
toms of IBS.
Recently, the recommendation on primary end-
points to be used in trials for IBS has been 
changed from a co-primary endpoint of global 
Therapeutic Advances in Gastroenterology 10(3)
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assessment and pain to the separate evaluation of 
efficacy on stool-related abnormalities and on 
pain [European Medicines Agency, 2014]. In our 
pooled analysis, we found that OB improved both 
the intensity and the frequency of abdominal pain 
(Figure 2). The weak effect of OB administration 
on stool frequency and consistency we revealed 
could be attributed to an over-simplistic dicho-
tomic analysis (normal/abnormal consistency 
instead of the specific Bristol scale) as well as to 
the relevant placebo effect, as the OBIS study 
showed a slight but significant reduction of stool 
frequency at the end of the OB treatment [Clave 
et al. 2011].
IBS is a chronic and relapsing disease with cyclic 
periods of symptoms and frequent relapses to 
short [Jones et al. 1999] and long-term treatments 
[Chey et  al. 2004]. Antispasmodics are recom-
mended as first line treatment for IBS patients 
with pain and bloating as dominant symptoms, 
but there is no agreement on the type of protocol 
to be selected for treatment (continuous, cyclic or 
intermittent, or ‘on demand’). Recently, an initial 
approach of 2–3 months’ treatment has been 
shown to be effective in most patients [Evangelista, 
2012; Boeckxstaens et al. 2013], as also supported 
by the relevant therapeutic effect observed at 10 
and 15 weeks in this pooled analysis. However, 
symptom relapse occurs in up to 50% of IBS 
patients, making cyclic treatment necessary. 
Consequently, only well-tolerated drugs with 
proved effects on the specific relapsing symptoms 
should be used [Boeckxstaens et al. 2013]. The 
OBIS study revealed that the therapeutic effect of 
OB during the 10-week follow-up period subse-
quent to the 15-week treatment period remained 
greater than the effect of placebo in terms of 
relapse-free probability and withdrawal rate due 
to symptom relapse [Clave et al. 2011].
Considering the results from this pooled analysis 
together with the outcomes from previous stud-
ies, we can conclude that OB is well tolerated, has 
a strong therapeutic effect on abdominal pain, 
bloating and rate of responders as assessed by 
patients and by physicians, and prevents symp-
tom relapse. OB has been on the market for over 
30 years in over 40 countries in Europe, Central 
America, Asia (China, India, Pakistan, Korea and 
Philippines), the Middle East, and Africa (Egypt, 
French African countries). Our findings further 
support the therapeutic utility of OB in clinical 
practice.
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